e-Therapeutics finds CEO in Amgen

e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.

At that time, he will also be seated to the e-Therapeutics board of Directors.

Dr. Barlow, is working for Amgen in Switzerland. He has also experience in scientific, business and corporate leading roles working for Astra Zeneca, Crucell and Johnson and Johnson. He will move from Switzerland to Oxford.

e-Therapeutics’ Chairman, Iain Ross has welcomed Barlow’s experience, and has said that he expects the new CEO to lead the company’s development and achieve short and long term goals.

“I would also like to take this opportunity to thank the e-Therapeutics team for the tremendous effort they have made over the last six months whilst the business has been in transition and has refocused its strategy,” said Ross.

Dr. Barlow in his comment praised e-Therapeutics’ approach to drug discovery: “I believe that e-Therapeutics’ computational-based, network biology approach provides a valuable, productive and differentiated means to create novel medicines to treat inherently complex diseases.”

Dr. Barlow also said that he’d continue on building the network pharmacology platform, generating additional supporting data for the internal programmes, and communicating to the industry the utility of this approach in addressing some of the biggest challenges it faces in treating serious and debilitating diseases.

“I am looking forward to working with the e-Therapeutics’ team and driving the Company forward to reach its full potential,” Dr. Barlow said